Hakutulokset - Richard D. DiMarchi

Tarkenna hakua
  1. 1
    Fibroblast growth factor 21 night watch: advances and uncertainties in the field

    Fibroblast growth factor 21 night watch: advances and uncertainties in the field Tekijä Alexei Kharitonenkov, Richard D. DiMarchi

    Julkaistu 2016
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  2. 2
    Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety

    Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety Tekijä Rongjun He, Brian Finan, John P. Mayer, Richard D. DiMarchi

    Julkaistu 2019
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  3. 3
    Anti-obesity drug discovery: advances and challenges

    Anti-obesity drug discovery: advances and challenges Tekijä Timo D. Müller, Matthias Blüher, Matthias H. Tschöp, Richard D. DiMarchi

    Julkaistu 2021
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  4. 4
    Anti-Obesity Therapy: from Rainbow Pills to Polyagonists

    Anti-Obesity Therapy: from Rainbow Pills to Polyagonists Tekijä Timo D. Müller, Christoffer Clemmensen, Brian Finan, Richard D. DiMarchi, M. Tschöp

    Julkaistu 2018
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  5. 5
    Optimization of the Native Glucagon Sequence for Medicinal Purposes

    Optimization of the Native Glucagon Sequence for Medicinal Purposes Tekijä Joseph R. Chabenne, Maria A. DiMarchi, Vasily M. Gelfanov, Richard D. DiMarchi

    Julkaistu 2010
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  6. 6
    Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology

    Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology Tekijä Sara J. Brandt, Timo D. Müller, Richard D. DiMarchi, M. Tschöp, Kerstin Stemmer

    Julkaistu 2018
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  7. 7
    Insulin analogues and their potential in the management of diabetes mellitus

    Insulin analogues and their potential in the management of diabetes mellitus Tekijä Geremia B. Bolli, Richard D. Di Marchi, G. D. Park, Stig Pramming, Veikko A Koivisto

    Julkaistu 1999
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  8. 8
    Effect of targeted estrogen delivery using glucagon-like peptide-1 on insulin secretion, insulin sensitivity and glucose homeostasis

    Effect of targeted estrogen delivery using glucagon-like peptide-1 on insulin secretion, insulin sensitivity and glucose homeostasis Tekijä Joseph P. Tiano, Chandra R. Tate, Bin Yang, Richard D. DiMarchi, Franck Mauvais‐Jarvis

    Julkaistu 2015
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  9. 9
    Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes

    Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes Tekijä Megan E. Capozzi, Richard D. DiMarchi, Matthias H. Tschöp, Brian Finan, Jonathan E. Campbell

    Julkaistu 2018
    Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  10. 10
    The metabolic actions of glucagon revisited

    The metabolic actions of glucagon revisited Tekijä Kirk M. Habegger, Kristy M. Heppner, Nori Geary, Timothy J. Bartness, Richard D. DiMarchi, Matthias H. Tschöp

    Julkaistu 2010
    Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  11. 11
    Gαs regulates Glucagon-Like Peptide 1 Receptor-mediated cyclic AMP generation at Rab5 endosomal compartment

    Gαs regulates Glucagon-Like Peptide 1 Receptor-mediated cyclic AMP generation at Rab5 endosomal compartment Tekijä Shravan Babu Girada, Ramya S. Kuna, Shilpak Bele, Zhimeng Zhu, N.R. Chakravarthi, Richard D. DiMarchi, Prasenjit Mitra

    Julkaistu 2017
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  12. 12
    Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice

    Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice Tekijä Kristy M. Heppner, Sarah Marks, Jenna Holland, Nickki Ottaway, David L. Smiley, Richard D. DiMarchi, Diego Pérez–Tilve

    Julkaistu 2015
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  13. 13
    Peptide lipidation stabilizes structure to enhance biological function

    Peptide lipidation stabilizes structure to enhance biological function Tekijä Brian Ward, Nickki Ottaway, Diego Pérez–Tilve, Dejian Ma, Vasily M. Gelfanov, Matthias H. Tschöp, Richard D. DiMarchi

    Julkaistu 2013
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  14. 14
    GLP-1/glucagon receptor co-agonism for treatment of obesity

    GLP-1/glucagon receptor co-agonism for treatment of obesity Tekijä Miguel A. Sánchez-Garrido, Sara J. Brandt, Christoffer Clemmensen, Timo D. Müller, Richard D. DiMarchi, Matthias H. Tschöp

    Julkaistu 2017
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  15. 15
    Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism

    Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism Tekijä Piotr Mróz, Brian Finan, Vasily M. Gelfanov, Bin Yang, Matthias H. Tschöp, Richard D. DiMarchi, Diego Pérez–Tilve

    Julkaistu 2018
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  16. 16
    GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications

    GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications Tekijä Jonathan E. Campbell, Timo D. Müller, Brian Finan, Richard D. DiMarchi, Matthias H. Tschöp, David A. D’Alessio

    Julkaistu 2023
    Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  17. 17
    Unimolecular Polypharmacy for Treatment of Diabetes and Obesity

    Unimolecular Polypharmacy for Treatment of Diabetes and Obesity Tekijä Matthias H. Tschöp, Brian Finan, Christoffer Clemmensen, Vasily M. Gelfanov, Diego Pérez–Tilve, Timo D. Müller, Richard D. DiMarchi

    Julkaistu 2016
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  18. 18
    Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes

    Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes Tekijä Qiming Tan, Seun Akindehin, Camila E. Orsso, Richelle C. Waldner, Richard D. DiMarchi, Timo D. Müller, Andrea M. Haqq

    Julkaistu 2022
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  19. 19
    A glucagon analog chemically stabilized for immediate treatment of life-threatening hypoglycemia

    A glucagon analog chemically stabilized for immediate treatment of life-threatening hypoglycemia Tekijä Joseph R. Chabenne, Maria DiMarchi Chabenne, Yan Zhao, Jay J. Levy, David L. Smiley, Vasily M. Gelfanov, Richard D. DiMarchi

    Julkaistu 2014
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  20. 20
    Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice

    Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice Tekijä Sigrid Jall, Stephan Sachs, Christoffer Clemmensen, Brian Finan, Frauke Neff, Richard D. DiMarchi, Matthias H. Tschöp, Timo D. Müller, Susanna M. Hofmann

    Julkaistu 2017
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:

Työkalut: